Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Free Cash Flow (2017 - 2025)

Protagonist Therapeutics (PTGX) has disclosed Free Cash Flow for 9 consecutive years, with -$37.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 25.88% to -$37.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56.1 million through Dec 2025, down 69.32% year-over-year, with the annual reading at $56.1 million for FY2025, 69.32% down from the prior year.
  • Free Cash Flow hit -$37.1 million in Q4 2025 for Protagonist Therapeutics, down from -$3.3 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $268.4 million in Q2 2024 to a low of -$37.9 million in Q1 2022.
  • Historically, Free Cash Flow has averaged -$2.5 million across 5 years, with a median of -$27.3 million in 2023.
  • Biggest YoY gain for Free Cash Flow was 1121.12% in 2024; the steepest drop was 274.06% in 2024.
  • Year by year, Free Cash Flow stood at -$27.1 million in 2021, then fell by 19.29% to -$32.4 million in 2022, then skyrocketed by 152.34% to $16.9 million in 2023, then tumbled by 274.06% to -$29.5 million in 2024, then fell by 25.88% to -$37.1 million in 2025.
  • Business Quant data shows Free Cash Flow for PTGX at -$37.1 million in Q4 2025, -$3.3 million in Q3 2025, and -$28.3 million in Q2 2025.